1. Home
  2. HALO vs SNEX Comparison

HALO vs SNEX Comparison

Compare HALO & SNEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$78.05

Market Cap

8.1B

Sector

Health Care

ML Signal

HOLD

Logo StoneX Group Inc.

SNEX

StoneX Group Inc.

HOLD

Current Price

$106.28

Market Cap

9.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
HALO
SNEX
Founded
1998
1924
Country
United States
United States
Employees
N/A
5400
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
9.1B
IPO Year
2001
1996

Fundamental Metrics

Financial Performance
Metric
HALO
SNEX
Price
$78.05
$106.28
Analyst Decision
Buy
Strong Buy
Analyst Count
11
1
Target Price
$78.64
$81.33
AVG Volume (30 Days)
1.8M
1.0M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.22
3.74
Revenue
$151,862,000.00
$132,378,200,000.00
Revenue This Year
$28.24
N/A
Revenue Next Year
$12.56
$4.17
P/E Ratio
$63.51
$29.66
Revenue Growth
N/A
32.53
52 Week Low
$55.64
$68.97
52 Week High
$82.26
$141.99

Technical Indicators

Market Signals
Indicator
HALO
SNEX
Relative Strength Index (RSI) 59.28 35.81
Support Level $67.12 $105.27
Resistance Level $82.24 $129.45
Average True Range (ATR) 2.46 6.53
MACD -0.33 -2.26
Stochastic Oscillator 46.95 5.07

Price Performance

Historical Comparison
HALO
SNEX

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About SNEX StoneX Group Inc.

StoneX Group Inc is a brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.

Share on Social Networks: